Our people

We are a dedicated team of experts focused on the implementation of continuous biomanufacturing for drug substance and the development of oral formulation for drug product. Our primary objective is to reduce production costs and improve accessibility, ensuring that life-saving and life-comforting biologics reach patients in need. The Biosanapharma team has multiple years of experience with biosimilar development and fully documented GMP continuous manufacturing, including interactions with FDA/EMA.

Management

Ard Tijsterman, Jaap den Engelsman, Menne Zaalberg and Maarten Pennings.

Antibody

Core Values

 

Honed Expertise

A core, non-negotiable value is our constant pursuit of expertise. Continuously growing and evolving as we progress our technologies and products.

Reliable

Trust is built over time, but it also must be maintained and nurtured. That is why our management and operations prioritise reliability in every interaction. 

Challenging the limits of biologics manufacturing

Innovation requires persistence and curiosity, we seek to constantly evolve approaches in biologics manufacturing by challenging the limits that stand in the way of progress.

Working for a better world

We recognize that the changes we can make in development and biomanufacturing of biologics have the potential to create lasting and meaningful global change. This belief fuels our decisions and informs our approach.

Antibody
top curve

Board of Directors (BoD)

Bert Tjeenk Willink 
Worked for Boehringer Ingelheim for 25 years, from 2008 to 2012 as Board member. Since then he acts as interim CEO and Board member for various (bio)pharma companies, among which Stada AG, which he sold to Private Equity in 2017.

Ard Tijsterman 
CEO at BiosanaPharma.

Jan Karel Mak 
Fulfilled leadership roles in engineering firms in the Netherlands and served as management consultant. Currently coach, supervisor and investor in various technically oriented companies.

Jaap den Engelsman 
CFO at BiosanaPharma.

Scientific Advisory Board

Prof Stephen Mahler

Professor Stephen Mahler is a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology and Director of the Australian Research Council Training Centre for Biopharmaceutical Innovation (CBI), University of Queensland. 

 

Dr Ben Rademaker

Ben Rademaker has over 40 years of experience in drug development and drug formulation. He worked in academia and industry and is the founder and co-owner of InProPharma BV. 

DR Jaap Wieling

Jaap is CEO of PureIMS, a company specialized in innovative inhaled therapies. Before that he held executive and research management roles in R&D institutions and commercial research and manufacturing corporations (Biosanapharma, Xendo, TNO, PRA/ICON, DSM).